A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Neoplasm

Interventions

DRUG: TSN1611
DRUG: TSN1611
DRUG: TSN1611
DRUG: TSN1611

Sponsor

Tyligand Pharmaceuticals (Suzhou) Limited